We also identified that clinicians
Among chronic patients, those who have never used olanzapine/clozapine before had a significantly higher increase in weight and BMI than those who have
We included only RCTs recruiting people of both sexes, aged 18 years or more, with a diagnosis of treatment‐resistant schizophrenia (or related disorders) and
Olanzapine is a second-generation (atypical) antipsychotic medication
Objective: To examine the pharmacokinetic implications and potential clinical effects of tobacco smoking cessation in patients on stable clozapine or olanzapine treatment
Chronically, olanzapine or clozapine was self-administered via cookie dough to rodents (Sprague-Dawley or Wistar rats; C57Bl/6J or A/J mice)
There are others who are unable to tolerate a high dosage of clozapine
The identified doses were then used to calculate equivalence ratios
Thus, second-generation antipsychotics, and in particular clozapine, might be effective even in patients with conduct disorder
One possible basis for the difference in incidence of agranulocytosis between clozapine and olanzapine is that the therapeutic
Of the total drug interactions, 468 are major, 443 are moderate, and 7 are minor
Olanzapine and clozapine determine the most metabolic disturbances; aripiprazole, brexpiprazole, and cariprazine had the fewest metabolic side effects, making them the safest to use
On stopping smoking, reduce the dose gradually over a week until around 75% of the original dose is reached
Olanzapine is used to treat schizophrenia
Olanzapine (1 to 8 mg/kg), but not clozapine, increased body weight in female rats only
At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not Introduction